Consolidated Sales Target of ¥32 Billion for the Fiscal Year Ending March 2027
First written in FY2023. 7 of 10 entries say "Restated". Latest entry: 2026-08-06.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2026-H1RestatedAnnual report
「The Group has formulated a medium-term management plan targeting consolidated revenue of ¥31.0 billion for FY2028. With the water-ionizer sales business as its core, we will vigorously develop the bottled-water, electrolyzed-water dialysis and regenerative-medicine businesses, aiming to achieve the medium-term management plan and enhance corporate value over the medium to long term.」
The Company reconfirmed its medium-term management plan targeting consolidated revenue of ¥31 billion for the fiscal year ending March 2028 and its business structure centered on water ionizers, with operations in bottled water, electrolyzed-water dialysis and regenerative medicine. - FY2025SoftenedAnnual report
「The Group had set a target of ¥32 billion in consolidated revenue for the fiscal year ending March 2027, but after analyzing the current status of its water ionizer sales business and Group companies and reviewing its future targets and the measures to achieve them, it has formulated a new medium-term management plan targeting consolidated revenue of ¥31 billion for the fiscal year ending March 2028.」
The consolidated revenue target changed from ¥32 billion for the fiscal year ending March 2027 to ¥31 billion for the fiscal year ending March 2028, extending the deadline while reducing the amount. - FY2025-H1RestatedAnnual report
「The Group has set a target of ¥32 billion in consolidated revenue for the fiscal year ending March 2027 and, to achieve this and increase corporate value over the medium to long term, is focusing on the following 3 areas: 1. Quantitative expansion of the direct-sales division of its core water ionizer business; 2. Expansion of overseas operations in the wholesale and OEM divisions of the water ionizer business; and 3. The rollout of electrolyzed-water dialysis ahead of the rest of the world, together with research and development and other activities aimed at potential insurance coverage.」
The Company reconfirmed its ¥32 billion consolidated revenue target for the fiscal year ending March 2027 and 3 priority initiatives: quantitative expansion of direct sales, overseas expansion of wholesale and OEM operations, and the rollout and research and development of electrolyzed-water dialysis. - FY2024-Q3RestatedAnnual report
「The Group has set a target of ¥32 billion in consolidated revenue for the fiscal year ending March 2027 and, to achieve this and increase corporate value over the medium to long term, is focusing on the following 3 areas: 1. Quantitative expansion of the direct-sales division of its core water ionizer business, together with greater efficiency 2. Expansion of overseas operations in the wholesale and OEM divisions of the water ionizer business 3. The rollout of electrolyzed-water dialysis ahead of the rest of the world, together with research and development and other activities aimed at potential insurance coverage」
The Company reconfirmed its ¥32 billion consolidated revenue target for the fiscal year ending March 2027 and 3 priority initiatives: quantitative expansion of direct sales, overseas expansion of wholesale and OEM operations, and the rollout and research and development of electrolyzed-water dialysis. - FY2024-Q2RestatedAnnual report
「The Group has set a target of ¥32 billion in consolidated revenue for the fiscal year ending March 2027 and, to achieve this and increase corporate value over the medium to long term, is focusing on the following 3 areas: 1. Quantitative expansion of the direct-sales division of its core water ionizer business, together with greater efficiency 2. Expansion of overseas operations in the wholesale and OEM divisions of the water ionizer business 3. The rollout of electrolyzed-water dialysis ahead of the rest of the world, together with research and development and other activities aimed at potential insurance coverage」
The Company reconfirmed its ¥32 billion consolidated revenue target for the fiscal year ending March 2027 and 3 priority initiatives: quantitative expansion of direct sales, overseas expansion of wholesale and OEM operations, and the rollout and research and development of electrolyzed-water dialysis. - FY2024-Q1RestatedAnnual report
「The Group has set a target of ¥32 billion in consolidated revenue for the fiscal year ending March 2027 and, to achieve this and increase corporate value over the medium to long term, is focusing on the following 3 areas: 1. Quantitative expansion of the direct-sales division of its core water ionizer business, together with greater efficiency 2. Expansion of overseas operations in the wholesale and OEM divisions of the water ionizer business 3. The rollout of electrolyzed-water dialysis ahead of the rest of the world, together with research and development and other activities aimed at potential insurance coverage」
The Company reconfirmed its ¥32 billion consolidated revenue target for the fiscal year ending March 2027 and 3 priority initiatives: quantitative expansion of direct sales, overseas expansion of wholesale and OEM operations, and the rollout and research and development of electrolyzed-water dialysis. - FY2023First statedAnnual report
「The Group has set a target of ¥32 billion in consolidated revenue for the fiscal year ending March 2027 and, to achieve this and increase corporate value over the medium to long term, will focus on the following 3 areas: 1. Quantitative expansion of the direct-sales division of its core water ionizer business, together with greater efficiency; 2. Expansion of overseas operations in the wholesale and OEM divisions of the water ionizer business; and 3. The rollout of electrolyzed-water dialysis ahead of the rest of the world, together with research and development and other activities aimed at potential insurance coverage.」
The Company disclosed for the first time its ¥32 billion consolidated revenue target for the fiscal year ending March 2027 and 3 priority initiatives: quantitative expansion of direct sales, overseas expansion of wholesale and OEM operations, and the rollout and research and development of electrolyzed-water dialysis.